The currently preferred radiopharmaceutical for positron emission tomography (PET) in
oncology is 2-[18 F] fluoro-deoxyglucose (FDG). Increased accumulation of this …

[18 F] fluoro-2-deoxy-d-glucose (FDG) is currently the only fluorinated tracer used in routine
clinical positron emission tomography (PET). Fluorine-18 is considered the ideal …

The purpose of the study was to evaluate the 6-[18F] fluoro-l-dopa (FDOPA) kinetics with
PET in patients with treated melanoma metastases and to compare it with the standard …

We studied the tumor uptake and metabolism of 4-borono-2-[18 F] fluoro-d, l-phenylalanine
([18 F] FBPA), an 18 F-labeled target compound for boron neutron capture therapy. In mice …

Large neutral l-amino acids are substrates of system L amino acid transporters. The level of
one of these, LAT1, is increased in many tumors. Aromatic l-amino acids may also be …

Increased metabolism in a number of cellular pathways is a common feature of malignant
tumors. This metabolic hallmark of neoplastic tissue led to the development of …

Abstract The potential of 4-borono-2-[18 F] fluoro-d, l-phenylalanine ([18 F] FBPA), a
fluorinated derivative of a target compound for boron neutron capture therapy, for melanoma …

Background Skin cancers are the most common of all cancers, with the most aggressive
cutaneous malignancies including malignant melanoma, cutaneous squamous cell …

The purpose of the study was to assess the feasibility of PET and L-[methyl-11C] methionine
(11C-methionine) in the detection of malignantmelanomaMethods …

The cellular distribution of 4-borono-2-[18F] fluoro-L-phenylalanine ([18F] FBPA, an analog
of p-boronophenylaline), a potential agent for boron neutron capture therapy (BNCT), and [6 …